Sen. Bernie Sanders sent a letter to Moderna's CEO urging the company to reconsider its price per dose in light of the federal government's role in developing the vaccine.

The FDA is increasingly hesitant on allowing drugmakers to test their cell and gene therapy candidates in human trials, The Wall Street Journal reported Jan. 10. 

With the COVID-19 public health emergency approaching an end date and some vaccine-makers prepping for their shots to plunge into the U.S. market, many anticipate nasal COVID-19 vaccines to join the fray. 

Navitus Health Solutions and Banjo Health are partnering to modernize and streamline prior authorization workflows for health plan clients, members and prescribers.

The American Hospital Association said it's "disappointed" after a district court ruled to return a 340B funding case back to HHS to determine the appropriate remedy for the delayed payments, according to a Jan. 10 statement. 

Moderna is ruminating about pricing its COVID-19 vaccine to cost between $110 and $130 once the federal government stops paying for it, The Wall Street Journal reported Jan. 9. 

Caremark, Express Scripts and OptumRx — the three largest pharmacy benefit managers in the U.S. — increased the number of drugs excluded from their formularies in 2023, according to a Jan. 10 blog post from the Drug Channels Institute.

Moderna's revenue from its COVID-19 vaccine is expected to drop 72.8 percent, from $18.4 billion to a minimum of $5 billion, from 2022 to 2023's annual sales, the company said Jan. 9. 

With multiple retail pharmacies short on medicine cabinet staples amid a rise in flu and respiratory syncytial virus cases, St. Louis-based SSM Health's pharmacy leader told the Wisconsin State Journal some drug shortage tips. 

An Iowa pharmacy is relying on "old school" methods to provide liquid forms of common medications to children, ABC affiliate KCCI reported Jan. 8.

Evusheld, the only COVID-19 preexposure prophylaxis treatment with emergency use authorization, may not be effective against subvariant XBB.1.5, which makes up nearly 3 in 10 cases, the FDA said Jan. 6. 

The FDA handed Biogen and Eisai's new Alzheimer's drug accelerated approval Jan. 6. 

The FDA accepted Pfizer for a priority review of a supplemental Biologics License Application for its pneumococcal conjugate vaccine for children.

Moderna and CytomX Therapeutics, a cancer drug company, will collaborate to develop investigational mRNA-based therapies, the companies said Jan. 5. 

The FDA accepted AstraZeneca and Sanofi's application for their pediatric respiratory syncytial virus drug Jan. 5, and if approved, it would be the first single-dose preventive option for a virus that infects nearly all children before the age of 2. 

Millions of Paxlovid packets haven't been used, which could be tied to COVID-19 rebound risks, less federal funds and diminishing public concern about the pandemic, according to an article published Jan. 3 in Nature. 

After the FDA said it would allow some retail pharmacies to dispense prescribed abortion pills, Walgreens and CVS told Becker's they plan to distribute the drug mifepristone. 

As retail pharmacy chains ration sales of children's pain medications amid a national shortage, some physicians are delaying operations as families scramble for medicine cabinet staples. 

The following 10 hospitals, health systems and hospital operators have posted job listings seeking pharmacy leaders in the last week.

Three drugmakers each have four blood pressure drugs in short supply after some were recalled in 2022 because of the presence of nitrosamine, which the FDA has labeled as a "probable human carcinogen."